welcome to oneFAPvoice
- a positively charged Familial Adenomatous Polyposis community.- join today!
- login
Sucampo Enters Into Exclusive Option and Collaboration Agreement With Cancer Prevention Pharmaceuticals for Development of Late-Stage CPP-1X/Sulindac Combination for Familial Adenomatous Polyposis
Sucampo Pharmaceuticals, Inc., a global biopharmaceutical company, today announced an option and collaboration agreement under which Cancer Prevention Pharmaceuticals, Inc. (CPP) has granted Sucampo the sole option to acquire an exclusive license to commercialize CPP-1X/sulindac combination product in North America. This product is currently in a Phase 3 clinical trial for the treatment of familial adenomatous polyposis (FAP).
expertly curated content related to this topic
- Maria Blazo, MDSpecialization: Medical GeneticsEduc...
- Role of Surgery in Familial Adenomatous Polyposis and Hereditary Non Polyposis Colorectal Cancer (Lynch Syndrome)Surgery remains the mainstay of treatmen...
- Carcinoma Colon and Managementhttp://www.slideshare.net/shivkishor/car...
- FAPtalk Newsletter – Spring Issue 2017Click here to view our Spring 2017 FA...
- Peter G. Deveaux, MDPeter G. Deveaux is an Assistant Profess...
- Kelsey BreenKelsey Breen is a Genetic Counselor....
- Banner MD Anderson Cancer CenterAt Banner MD Anderson Cancer Center, col...
English
Portuguese